USFDA classifies Cipla Goa facility as VAI
Mumbai: Through a recent BSE filing, Cipla has informed that the United States Food and Drug Administration (USFDA) has classified the routine current Good Manufacturing Practices (cGMP) inspection at the Company's manufacturing facility in Goa as Voluntary Action Indicated (VAI).
The inspection was held from 10th – 21st June, 2024.
Read also: Cipla UK arm inks pact to purchase 6.9124 percent stake in Cipla Jiangsu Pharma
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets. It has strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS segments. It has 47 manufacturing sites around the world which produces 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to its 80+ markets.
Read also: Cipla, Alkem vie for Rs 4,000 crore stake in India's largest stent manufacturer: Report
